Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Overall strong Group performance 2022 CHFM 2021 Change in % CHFM CHF CER Sales 32,295 30,713 5 5 Core operating profit 12,668 11,652 9 9 as % of sales 39.2 37.9 Core net income 10,160 9,527 7 7 as % of sales 31.5 31.0 Core EPS (CHF) 11.76 10.56 11 11 IFRS net income 9,161 8,216 12 12 as % of sales 28.4 26.8 Operating free cash flow 9,782 8,117 21 21 as % of sales 30.3 26.4 Free cash flow 7,097 6,038 18 18 as % of sales 22.0 19.7 CER-Constant Exchange Rates Roche 52 52

View entire presentation